BNP Paribas Financial Markets Has $16.63 Million Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

BNP Paribas Financial Markets raised its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 13.8% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 90,083 shares of the medical research company's stock after buying an additional 10,912 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.18% of Charles River Laboratories International worth $16,629,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in CRL. Pinnacle Bancorp Inc. raised its stake in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after purchasing an additional 65 shares in the last quarter. Optiver Holding B.V. bought a new stake in shares of Charles River Laboratories International during the fourth quarter valued at about $37,000. GeoWealth Management LLC raised its position in Charles River Laboratories International by 311.5% in the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after acquiring an additional 190 shares in the last quarter. Pilgrim Partners Asia Pte Ltd bought a new stake in Charles River Laboratories International in the fourth quarter worth about $48,000. Finally, Tortoise Investment Management LLC raised its position in Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after acquiring an additional 115 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Performance

Shares of CRL traded down $1.30 during mid-day trading on Thursday, hitting $137.65. The company's stock had a trading volume of 330,267 shares, compared to its average volume of 977,404. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $254.15. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The firm has a market capitalization of $6.76 billion, a PE ratio of 916.77, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. The stock's 50-day moving average is $136.67 and its two-hundred day moving average is $165.60.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. The business had revenue of $984.17 million for the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm's revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.27 earnings per share. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their price target for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. UBS Group reissued a "neutral" rating and issued a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday. Evercore ISI raised Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 target price on the stock in a research note on Thursday, May 8th. Finally, Mizuho lowered their target price on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $172.31.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This trade represents a 18.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Birgit Girshick bought 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now directly owns 55,058 shares of the company's stock, valued at $9,064,198.54. This represents a 2.83% increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).